Cethromycin-Mediated Protection against the Plague Pathogen Yersinia pestis in a Rat Model of Infection and Comparison with Levofloxacin

Author:

Rosenzweig Jason A.,Brackman Sheri M.,Kirtley Michelle L.,Sha Jian,Erova Tatiana E.,Yeager Linsey A.,Peterson Johnny W.,Xu Ze-Qi,Chopra Ashok K.

Abstract

ABSTRACTThe Gram-negative plague bacterium,Yersinia pestis, has historically been regarded as one of the deadliest pathogens known to mankind, having caused three major pandemics. After being transmitted by the bite of an infected flea arthropod vector,Y. pestiscan cause three forms of human plague: bubonic, septicemic, and pneumonic, with the latter two having very high mortality rates. With increased threats of bioterrorism, it is likely that a multidrug-resistantY. pestisstrain would be employed, and, as such, conventional antibiotics typically used to treatY. pestis(e.g., streptomycin, tetracycline, and gentamicin) would be ineffective. In this study, cethromycin (a ketolide antibiotic which inhibits bacterial protein synthesis and is currently in clinical trials for respiratory tract infections) was evaluated for antiplague activity in a rat model of pneumonic infection and compared with levofloxacin, which operates via inhibition of bacterial topoisomerase and DNA gyrase. Following a respiratory challenge of 24 to 30 times the 50% lethal dose of the highly virulentY. pestisCO92 strain, 70 mg of cethromycin per kg of body weight (orally administered twice daily 24 h postinfection for a period of 7 days) provided complete protection to animals against mortality without any toxic effects. Further, no detectable plague bacilli were cultured from infected animals' blood and spleens following cethromycin treatment. The antibiotic was most effective when administered to rats 24 h postinfection, as the animals succumbed to infection if treatment was further delayed. All cethromycin-treated survivors tolerated 2 subsequent exposures to even higher lethalY. pestisdoses without further antibiotic treatment, which was related, in part, to the development of specific antibodies to the capsular and low-calcium-response V antigens ofY. pestis. These data demonstrate that cethromycin is a potent antiplague drug that can be used to treat pneumonic plague.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Reference33 articles.

1. Characterization of the rat pneumonic plague model: infection kinetics following aerosolization of Yersinia pestis CO92;Agar;Microbes Infect.,2009

2. Biohazard: the chilling true story of the largest covert biological weapons program in the world - told from inside by the man who ran it;Alibek,1999

3. Prevention of bubonic and pneumonic plague using plant-derived vaccines;Alvarez;Biotechnol. Adv.,2010

4. Comparison of the immune response to three different Yersinia pestis vaccines in guinea pigs and langurs;Chen;J. Infect. Dis.,1974

5. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard—8th edition. M07-A8;Clinical and Laboratory Standards Institute,2009

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3